These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33512448)

  • 1. Activated protein C has a regulatory role in factor VIII function.
    Wilhelm AR; Parsons NA; Samelson-Jones BJ; Davidson RJ; Esmon CT; Camire RM; George LA
    Blood; 2021 May; 137(18):2532-2543. PubMed ID: 33512448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of factor VIII light-chain residues 2007-2016 to an activated protein C-interactive site.
    Takeyama M; Wakabayashi H; Fay PJ
    Thromb Haemost; 2013 Feb; 109(2):187-98. PubMed ID: 23224054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants.
    Gale AJ; Radtke KP; Cunningham MA; Chamberlain D; Pellequer JL; Griffin JH
    J Thromb Haemost; 2006 Jun; 4(6):1315-22. PubMed ID: 16706977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
    Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
    J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays.
    Radtke KP; Griffin JH; Riceberg J; Gale AJ
    J Thromb Haemost; 2007 Jan; 5(1):102-8. PubMed ID: 17059431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replacing the factor VIII C1 domain with a second C2 domain reduces factor VIII stability and affinity for factor IXa.
    Wakabayashi H; Fay PJ
    J Biol Chem; 2013 Oct; 288(43):31289-97. PubMed ID: 24030831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
    Yada K; Nogami K; Shinozawa K; Kitazawa T; Hattori K; Amano K; Fukutake K; Shima M
    Br J Haematol; 2018 Oct; 183(2):257-266. PubMed ID: 30125997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.
    Cramer TJ; Griffin JH; Gale AJ
    Pathophysiol Haemost Thromb; 2010; 37(1):17-23. PubMed ID: 20501981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V.
    Thorelli E; Kaufman RJ; Dahlbäck B
    J Biol Chem; 1998 Jun; 273(26):16140-5. PubMed ID: 9632668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo.
    Pipe SW; Eickhorst AN; McKinley SH; Saenko EL; Kaufman RJ
    Blood; 1999 Jan; 93(1):176-83. PubMed ID: 9864159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated factor X cleaves factor VIII at arginine 562, limiting its cofactor efficiency.
    Plantier JL; Rolli V; Ducasse C; Dargaud Y; Enjolras N; Boukerche H; Négrier C
    J Thromb Haemost; 2010 Feb; 8(2):286-93. PubMed ID: 19874476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.
    Siner JI; Iacobelli NP; Sabatino DE; Ivanciu L; Zhou S; Poncz M; Camire RM; Arruda VR
    Blood; 2013 May; 121(21):4396-403. PubMed ID: 23372167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IX.
    Bloem E; Meems H; van den Biggelaar M; Mertens K; Meijer AB
    J Biol Chem; 2013 Sep; 288(36):26105-26111. PubMed ID: 23884417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NXT007-mediated hemostatic potential is suppressed by activated protein C-catalyzed inactivation of activated factor V.
    Nakajima Y; Ogiwara K; Inaba K; Kitazawa T; Nogami K
    Res Pract Thromb Haemost; 2024 Jan; 8(1):102271. PubMed ID: 38115953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
    Saenko EL; Shima M; Gilbert GE; Scandella D
    J Biol Chem; 1996 Nov; 271(44):27424-31. PubMed ID: 8910322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential.
    Nakajima Y; Takeyama M; Oda A; Shimonishi N; Nogami K
    Blood Adv; 2023 Apr; 7(8):1436-1445. PubMed ID: 36322904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
    Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
    J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variable contributions of basic residues forming an APC exosite in the binding and inactivation of factor VIIIa.
    Takeyama M; Wintermute JM; Manithody C; Rezaie AR; Fay PJ
    Biochemistry; 2013 Apr; 52(13):2228-35. PubMed ID: 23480827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
    Baumgartner CK; Mattson JG; Weiler H; Shi Q; Montgomery RR
    J Thromb Haemost; 2017 Jan; 15(1):98-109. PubMed ID: 27496751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation at either Arg336 or Arg562 in factor VIII is insufficient for complete resistance to activated protein C (APC)-mediated inactivation: implications for the APC resistance test.
    Amano K; Michnick DA; Moussalli M; Kaufman RJ
    Thromb Haemost; 1998 Mar; 79(3):557-63. PubMed ID: 9531040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.